PH12021550213A1 - Methods for treating neurodegenerative disorders - Google Patents

Methods for treating neurodegenerative disorders

Info

Publication number
PH12021550213A1
PH12021550213A1 PH12021550213A PH12021550213A PH12021550213A1 PH 12021550213 A1 PH12021550213 A1 PH 12021550213A1 PH 12021550213 A PH12021550213 A PH 12021550213A PH 12021550213 A PH12021550213 A PH 12021550213A PH 12021550213 A1 PH12021550213 A1 PH 12021550213A1
Authority
PH
Philippines
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Application number
PH12021550213A
Other languages
English (en)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of PH12021550213A1 publication Critical patent/PH12021550213A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PH12021550213A 2018-08-01 2021-01-28 Methods for treating neurodegenerative disorders PH12021550213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PH12021550213A1 true PH12021550213A1 (en) 2021-11-03

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550213A PH12021550213A1 (en) 2018-08-01 2021-01-28 Methods for treating neurodegenerative disorders

Country Status (27)

Country Link
US (2) US12083082B2 (https=)
EP (1) EP3829563B1 (https=)
JP (1) JP7573512B2 (https=)
KR (1) KR102716959B1 (https=)
CN (1) CN112867485A (https=)
AU (1) AU2019315853B2 (https=)
BR (1) BR112021001739A2 (https=)
CL (1) CL2021000269A1 (https=)
DK (1) DK3829563T3 (https=)
EA (1) EA202190406A1 (https=)
ES (1) ES3011716T3 (https=)
FI (1) FI3829563T3 (https=)
HR (1) HRP20250206T1 (https=)
HU (1) HUE070101T2 (https=)
IL (1) IL280424B2 (https=)
LT (1) LT3829563T (https=)
MX (1) MX2021001287A (https=)
MY (1) MY206530A (https=)
PH (1) PH12021550213A1 (https=)
PL (1) PL3829563T3 (https=)
PT (1) PT3829563T (https=)
RS (1) RS66516B1 (https=)
SG (1) SG11202100767XA (https=)
SI (1) SI3829563T1 (https=)
SM (1) SMT202500080T1 (https=)
UA (1) UA130011C2 (https=)
WO (1) WO2020028290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014121083A1 (en) 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Also Published As

Publication number Publication date
CA3108150A1 (en) 2020-02-06
US12083082B2 (en) 2024-09-10
KR102716959B1 (ko) 2024-10-11
CN112867485A (zh) 2021-05-28
FI3829563T3 (fi) 2025-02-17
AU2019315853B2 (en) 2025-05-01
EA202190406A1 (ru) 2021-10-15
MX2021001287A (es) 2021-07-15
JP2021533128A (ja) 2021-12-02
PT3829563T (pt) 2025-02-18
US20210315847A1 (en) 2021-10-14
SG11202100767XA (en) 2021-02-25
HUE070101T2 (hu) 2025-05-28
IL280424A (en) 2021-03-01
US20250213507A1 (en) 2025-07-03
KR20210039415A (ko) 2021-04-09
MY206530A (en) 2024-12-19
CL2021000269A1 (es) 2021-06-18
SI3829563T1 (sl) 2025-05-30
ES3011716T3 (en) 2025-04-08
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
BR112021001739A2 (pt) 2021-04-27
IL280424B1 (en) 2024-09-01
RS66516B1 (sr) 2025-03-31
IL280424B2 (en) 2025-01-01
HRP20250206T1 (hr) 2025-04-11
PL3829563T3 (pl) 2025-04-07
AU2019315853A1 (en) 2021-03-18
WO2020028290A1 (en) 2020-02-06
DK3829563T3 (en) 2025-02-24
LT3829563T (lt) 2025-02-25
EP3829563A1 (en) 2021-06-09
JP7573512B2 (ja) 2024-10-25
SMT202500080T1 (it) 2025-03-12

Similar Documents

Publication Publication Date Title
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
ZA201900519B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer&#39;s disease
PH12022551228A1 (en) Trem2 antibodies and uses thereof
MX2024005935A (es) Metodos para aumentar la exposicion al plasma de sepiapterina.
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
WO2018023072A3 (en) Compounds and compositions and uses thereof
MX2022004759A (es) Métodos y composiciones para tratar enfermedades y trastornos hepáticos.
IL278813A (en) Gene therapy for Alzheimer&#39;s disease
MX378940B (es) Trastornos neurodegenerativos.
MX378739B (es) Compuestos de 2-oxindol.
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MX2021005502A (es) Composiciones y metodos para tratar enfermedades neurodegenerativas.
PH12021550213A1 (en) Methods for treating neurodegenerative disorders
IL280326A (en) Small RNA contracts for Alzheimer&#39;s disease
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
ZA202006126B (en) Compounds for treating alzheimer&#39;s disease
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
MX2017013694A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son utiles en el tratamiento de la enfermedad de alzheimer.
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER&#39;S MORBUS
WO2015186144A3 (en) Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases
AU2018903530A0 (en) Treatment for Alzheimer&#39;s Disease